By comparing CADASIL patients with mutations in EGFr 1–6 and EGFr 7–34, those in the EGFr 1–6 group had a 12-year earlier onset of stroke, lower survival, and higher WMH volume than those in the EGFr 7–34 group. This evidence concerns the gene EGFR and Stroke.